Indication DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

DUPIXENT PROVIDED SIGNIFICANT DECREASES IN SINUS OPACIFICATION

Significantly decreased LMK-CT score vs placebo at Week 24, with greater improvement at Week 52 in Trial 2 (secondary endpoint)1,2

BASELINE
WEEK 24

CT scan of patient from clinical trial. Individual results may vary.

Change in LMK-CT scores in Trial 2 (Secondary endpoint)1,2

DUPIXENT DEMonSTRATED Statistically significant REDUCTIonS IN OPACIFICATION across ALL Individual SINUSES1,2

  • Lund-Mackay computed tomography (LMK-CT) score (range 0 to 24): reduced score indicates improvement.
  • LSM, least squares mean; SOC, standard of care.

Identify CRSwNP
patients appropriate
for DUPIXENT

View Patients

References:

  1. Data on file, Sanofi US. Clinical overview (chronic rhinosinusitis with nasal polyposis). 2018.
  2. Data on file, Sanofi US. LIBERTY NP SINUS-52, CSR. 2018.